googlea5e4f24c126ec886.html
 
Alcresta_Therapeutics_Logo.jpg

Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital. Our RELiZORB® cartridge contains iLipase®, a patented microbead/enzyme technology that breaks down fat for easy ingestion and optimal absorption.

Contact us

Amy Whited

 Account Manager

 awhited@alcresta.com

(860) 305-6570

Website: Alcresta.com

General email: Info@alcresta.com